NBP
NovaBridge Biosciences American Depositary Shares (NBP)
Healthcare • NASDAQ • $1.32+4.78%
- Symbol
- NBP
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.32
- Daily Change
- +4.78%
- Market Cap
- $146.16M
- Trailing P/E
- N/A
- Forward P/E
- -1.19
- 52W High
- $5.97
- 52W Low
- $1.26
- Analyst Target
- $9.00
- Dividend Yield
- 0.00%
- Beta
- 1.60
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema;…
Company websiteResearch NBP on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.